COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, provides business up ...
Both the US and UK governments are encouraging the implementation of alternatives, including private markets, into DC schemes ...
Fourth Quarter Results Total revenues of $50.6 million, a 13% year-over-year improvement and exceeding the high end of prior guidanceOperating income of $5.2 million increased 78% year-over-year, outp ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results